Skip to main content
logo
Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
3.530
+0.060 (1.73%)
Aug 10, 2026, 9:55 AM EDT - Market open

Psyence Biomedical Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
-6.941.01-51.16-3.21-1.86
Depreciation & Amortization
0.0100--
Stock-Based Compensation
0.16-0.320.220.33
Other Adjustments
-0.15-4.3649.07-0.08-
Change in Receivables
0.03-0.10.11-0.110.1
Changes in Accounts Payable
0.01-0.36-1.041.660.03
Changes in Other Operating Activities
-1.260.07-0.25-0.070
Operating Cash Flow
-8.14-3.73-2.95-1.59-1.39
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-0-0.01-0.01--
Purchases of Intangible Assets
-0.5----
Purchases of Investments
-4----
Other Investing Activities
-0.01-0.01---0.03
Investing Cash Flow
-4.51-0.02-0.01--0.03

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Long-Term Debt Issued
-12.51.17-
Long-Term Debt Repaid
---0.15--1.63
Net Long-Term Debt Issued (Repaid)
-12.351.17-1.63
Issuance of Common Stock
13.968.15---
Net Common Stock Issued (Repurchased)
13.968.15---
Financing Cash Flow
13.969.152.351.17-1.63

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Cash Flow
1.315.4-0.6-0.42-3.05

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-8.14-3.74-2.95-1.59-1.39
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-14.74-121.22---
Levered Free Cash Flow
-8.171.72-50.1-0.45-1.6
Unlevered Free Cash Flow
-7.48-3.96-4.04-1.650.03
SEC Filings: 10-K · 10-Q